This is a StreetInsider.com Premium Only Page

(EDSA) – Accesswire

Apr 11, 2024 09:00 AM Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Apr 2, 2024 09:00 AM Edesa Biotech to Participate in Upcoming Investor Conferences

Mar 21, 2024 04:30 PM Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Mar 7, 2024 08:45 AM Edesa Biotech to Participate in Barclays Global Healthcare Conference

Mar 4, 2024 04:30 PM Edesa Biotech to Participate in Upcoming Dermatology Meetings

Feb 9, 2024 04:15 PM Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Jan 4, 2024 04:15 PM Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Dec 15, 2023 04:10 PM Edesa Biotech Reports Fiscal Year 2023 Results

Nov 20, 2023 04:05 PM Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Oct 26, 2023 04:05 PM Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 25, 2023 09:10 AM Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug

Oct 12, 2023 12:15 PM Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Oct 12, 2023 12:10 PM Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Oct 10, 2023 09:00 AM Edesa Biotech Announces One-for-Seven Reverse Share Split

Sep 28, 2023 08:15 AM Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Aug 9, 2023 04:15 PM Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Jul 26, 2023 09:00 AM Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Jun 28, 2023 07:55 AM Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Jun 27, 2023 08:15 AM Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

May 11, 2023 04:30 PM Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Apr 20, 2023 08:30 AM Edesa Biotech to Participate in Swiss Biotech Day

Apr 4, 2023 08:45 AM The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Mar 23, 2023 04:30 PM Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Mar 16, 2023 04:10 PM Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Mar 15, 2023 08:10 AM Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Feb 10, 2023 09:00 AM Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Feb 1, 2023 08:15 AM Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Jan 17, 2023 08:30 AM Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

Dec 20, 2022 08:30 AM FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Dec 16, 2022 09:00 AM Edesa Biotech Reports Fiscal Year 2022 Results

Dec 2, 2022 08:00 AM Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

Nov 3, 2022 09:00 AM Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Sep 30, 2022 08:00 AM Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Sep 8, 2022 04:30 PM Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

Sep 7, 2022 08:00 AM Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

Aug 12, 2022 04:30 PM Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

Aug 3, 2022 08:15 AM Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

Jul 11, 2022 08:30 AM Edesa Biotech to Present at ARDS Drug Development Summit

May 24, 2022 07:55 AM Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

May 19, 2022 04:30 PM Edesa Biotech to Present at H.C. Wainwright Global Investment Conference

May 19, 2022 04:30 PM Edesa Biotech to Present at H.C. Wainwright Global Investment Conference

May 13, 2022 08:55 AM Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

Apr 28, 2022 07:45 AM Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected

Mar 29, 2022 09:00 AM Edesa Biotech Appoints Strategy Expert to Board of Directors

Mar 24, 2022 04:30 PM Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering

Mar 22, 2022 08:00 AM Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Feb 17, 2022 08:00 AM Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

Feb 14, 2022 09:00 AM Edesa Biotech Reports Fiscal 1st Quarter 2022 Results

Jan 26, 2022 07:45 AM Edesa Biotech to Join Ontario Bioscience Panel Discussion

Jan 13, 2022 07:55 AM Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy